X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs AUROBINDO PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE AUROBINDO PHARMA CADILA HEALTHCARE/
AUROBINDO PHARMA
 
P/E (TTM) x 18.3 19.8 92.3% View Chart
P/BV x 4.1 3.7 111.5% View Chart
Dividend Yield % 1.0 0.3 293.3%  

Financials

 CADILA HEALTHCARE   AUROBINDO PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
AUROBINDO PHARMA
Mar-18
CADILA HEALTHCARE/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs558809 69.0%   
Low Rs362504 71.7%   
Sales per share (Unadj.) Rs116.3281.1 41.4%  
Earnings per share (Unadj.) Rs17.941.4 43.2%  
Cash flow per share (Unadj.) Rs23.150.9 45.5%  
Dividends per share (Unadj.) Rs3.502.50 140.0%  
Dividend yield (eoy) %0.80.4 199.9%  
Book value per share (Unadj.) Rs85.4199.4 42.8%  
Shares outstanding (eoy) m1,023.74585.88 174.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.02.3 169.3%   
Avg P/E ratio x25.715.9 162.1%  
P/CF ratio (eoy) x19.912.9 154.0%  
Price / Book Value ratio x5.43.3 163.5%  
Dividend payout %19.66.0 324.0%   
Avg Mkt Cap Rs m470,664384,630 122.4%   
No. of employees `00011.817.3 68.2%   
Total wages/salary Rs m18,54521,308 87.0%   
Avg. sales/employee Rs Th10,072.79,500.7 106.0%   
Avg. wages/employee Rs Th1,569.11,229.4 127.6%   
Avg. net profit/employee Rs Th1,547.71,397.9 110.7%   
INCOME DATA
Net Sales Rs m119,049164,666 72.3%  
Other income Rs m1,1321,020 111.0%   
Total revenues Rs m120,181165,686 72.5%   
Gross profit Rs m28,47537,718 75.5%  
Depreciation Rs m5,3885,580 96.6%   
Interest Rs m911777 117.2%   
Profit before tax Rs m23,30832,380 72.0%   
Minority Interest Rs m62831 2,000.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6448,183 69.0%   
Profit after tax Rs m18,29224,229 75.5%  
Gross profit margin %23.922.9 104.4%  
Effective tax rate %24.225.3 95.8%   
Net profit margin %15.414.7 104.4%  
BALANCE SHEET DATA
Current assets Rs m82,005121,878 67.3%   
Current liabilities Rs m60,72086,806 69.9%   
Net working cap to sales %17.921.3 83.9%  
Current ratio x1.41.4 96.2%  
Inventory Days Days73130 56.3%  
Debtors Days Days9868 143.8%  
Net fixed assets Rs m83,70381,037 103.3%   
Share capital Rs m1,024586 174.8%   
"Free" reserves Rs m86,421116,218 74.4%   
Net worth Rs m87,445116,804 74.9%   
Long term debt Rs m25,5514,512 566.3%   
Total assets Rs m180,653211,052 85.6%  
Interest coverage x26.642.7 62.3%   
Debt to equity ratio x0.30 756.4%  
Sales to assets ratio x0.70.8 84.5%   
Return on assets %10.611.8 89.7%  
Return on equity %20.920.7 100.8%  
Return on capital %22.027.4 80.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,68380,727 52.9%   
Fx outflow Rs m11,24234,700 32.4%   
Net fx Rs m31,44146,027 68.3%   
CASH FLOW
From Operations Rs m9,19319,548 47.0%  
From Investments Rs m-9,737-19,570 49.8%  
From Financial Activity Rs m5158,642 6.0%  
Net Cashflow Rs m-298,922 -0.3%  

Share Holding

Indian Promoters % 74.8 54.1 138.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 8.0 104.4%  
FIIs % 5.9 27.7 21.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.2 107.8%  
Shareholders   44,069 69,601 63.3%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  UNICHEM LAB  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open on a Positive Note; Realty & Auto Stocks Lead(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.2% while the Hang Seng is up 1.6%.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Dec 12, 2018 11:37 AM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - DR. DATSONS LABS COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS